The EU patent is a really clever piece of work.
That sets Cel-Sci up as the first preparation before radiation and chemo rather than as a cure that carries the burden of proof. But hey who knows what make misbehaving cells disappear along the way.....And as long as hospitals adopt that preparation as a protocol for their cancer patients, and that is EVERY cancer patient, the sky's the limit.
If Cel-Sci does not win, wouldn't the 117 patients from Pharmanet be still included into the 880? Why would the FDA want to add anymore now?
Likely the end date if the Inventiv enrolled gets, well, rolled back with Ergomed enrolling about 25 - 30 per month to make up the difference.
They will have to be discarded. The trial can only end March 2017. Then with luck the FDA takes 6 months to evaluate.
There isn't one. You either believe the hint given about the explosive nature of Cel-Sci or you don't .
The law firm backing Cel-Sci is betting that they will win.
The CRO working the trials with Cel-Sci invested in it mid-way through the trials.
Meanwhile, Cel-Sci is crazily diluted and in danger of another R/S to remain listed.
The management pay themselves a lot of investors' money before they got any product on sale.
Bashers consistently attack Cel-Sci on a daily basis to #$%$ away it's stock price.
Up to you to draw your own conclusion.
It seems you are alluding that the "outstanding indebtedness" means Cel-Sci but it can't be because there is no ruling on Inventiv vs Cel-Sci yet.
Why would anybody want a leak from a medical trial and have it jeopardized?
A hint from the conductor of the trial is the best there can ever be, and that was already provided.
Interesting POV. We are wishing more cancer patients can be cured, not exactly that more people get cancer. You can't control whether people will get cancer, but it is good they can be rid of it where they previously could not, which is what CVM and many other similar companies hope to achieve.